Fonogym Biotech completes $80 million in D1 round of financing, led by China National Regulatory Fund

On May 7, Virogin Biotech Limited announced that it has received USD 80 million in D1 round of financing.

Currently, VG161 is the product with the fastest research progress in the Fonova's biological product pipeline, which is in the clinical development stage.

According to reports, the mechanism of action of VG161 includes: 1) greatly improving the tumor microenvironment so that immune cells can reach the tumor tissue; 2) synergistically activating the innate and adaptive immune system through the expressed immune regulatory factors; 3) effective Transform anti-viral immunity into anti-tumor immunity; 4) Inhibit the anti-immune mechanism of tumor tissue itself to maximize the anti-tumor immune effect.

In addition to VG161, Fonova's follow-up product pipeline also includes the more efficient and safe VG200 series based on the core virus framework platform (already in the clinical application stage), the VG300 series expressing a combination of new immune regulatory factors, and exploring different routes of administration.

Regarding this financing, Mr.

Mr.